TITLE

Embryonic and Adult Stem Cells

AUTHOR(S)
Borge, Ole Johan
PUB. DATE
January 2004
SOURCE
Acta Veterinaria Scandinavica;2004 Supplement 1, Vol. 45, pS39
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the usefulness of the embryonic and adult stem cells in medical research. The use of embryonic stem cells is not progressive due to lack of funding, limited source of embryonic stem lines and a legislation prohibiting research with human embryos. On the other hand, adult stem cells are potential subject of clinical trials to develop future treatment of diseases in humans.
ACCESSION #
31725226

 

Related Articles

  • Derivation of GMP Raw Materials for Use in Regenerative Medicine: hESC-based Therapies, Progress Toward Clinical Application. Hewitt, Z. A.; Amps, K. J.; Moore, H. D. // Clinical Pharmacology & Therapeutics;Oct2007, Vol. 82 Issue 4, p448 

    The potential of somatic cell therapies from human embryonic stem cells (hESCs) as alternatives to traditional drug-based remedies for treating some of mankind's most debilitating diseases has resulted in the need to translate rapidly proof-of-principle and basic research into clinical...

  • Doctors accused of doing illegal stem-cell trials. Abbott, Alison // Nature;5/1/2008, Vol. 453 Issue 7191, p-1 

    The article features the lawsuit filed by Dieter Bollman, 70-year old patient, against Hannes Strasser in Austria. He consented to the surgery procedure because Strasser, a urologists at the University Hospital Innsbruck, told him that the treatment had a very high success rate and implied that...

  • FINDING ETHICALLY ACCEPTABLE SOLUTIONS FOR THERAPEUTIC HUMAN STEM CELL RESEARCH. Meyer, John R. // Ethics & Medicine: An International Journal of Bioethics;Spring2008, Vol. 24 Issue 1, p51 

    Katrien Devolder offers a compromise solution for the derivation of human embryonic stem cells that is designed to appease those who consider the killing of human embryos immoral. She proposes to build on a gradualist view of embryonic development in which the embryo merits special respect as...

  • Geron Soars as First ESC Trial Clears FDA Hurdle. Boggs, Jennifer // BioWorld Today;1/26/2009, Vol. 20 Issue 15, p1 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the Phase I trial of GRNOPCI, human embryonic stem cells (hESC)-derived oligodendrocytes of Geron Corp. in patients with spinal cord injury. Thomas Okarma, president and chief executive officer of Geron,...

  • Embryonic Stem-cell Therapy.  // PN;Apr2009, Vol. 63 Issue 4, p20 

    The article reports on the plans of Geron Corp. for a preliminary study on the safety of human embryonic stem cells (hESC) transplantation to patients with spinal cord injury (SCI). The biotechnology firm proposes to recruit patients with thoracic T3-10 injuries sustained within 7-14 days....

  • Research on embryonic stem cells: The time has come--maybe. Asch-Goodkin, Judith // Contemporary Pediatrics;Jun2005, Vol. 22 Issue 6, p12 

    This article looks at efforts to fund research on embryonic stem cells in the U.S. Embryonic stem cells have enormous therapeutic potential for a wide range of diseases and disabilities but, unhappily, existing techniques for extracting these amazing cells kill the embryo that contains them....

  • ES research in Australia.  // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Mar2007, Vol. 14 Issue 3, p355 

    The article discusses the outcome and recommendations of a review conducted by Judge Lockhart and an independent committee regarding the effects of embryonic stem cell research on human conception and possible therapies. The review observed that there was not a single view coming from the...

  • Special Cells, Special Considerations: The Challenges of Bringing Embryonic Stem Cells From the Laboratory to the Clinic. Addis, R. C.; Bulte, J. W. M.; Gearhart, J. D. // Clinical Pharmacology & Therapeutics;Mar2008, Vol. 83 Issue 3, p386 

    Human embryonic stem (ES) cells are an attractive tool for cell-based therapies because of their limitless capacity for proliferation and their ability to differentiate into all cell types of the body. However, these features introduce certain unique risks that must be considered in developing...

  • FDA ROUNDUP.  // MondayMorning;1/26/2009, Vol. 17 Issue 3, p1 

    The article reports on the approval given to Geron Corp. of Menlo Park, California by the U.S. Food & Drug Administration to begin the first human test of embryonic stem cells on humans. According to the article, the stem-cell test will attempt to restore movement to paralyze people by injecting...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics